Lv3
230 积分 2021-07-21 加入
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
5天前
已完结
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients
2个月前
已完结
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
3个月前
已完结
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
3个月前
已完结
Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects
3个月前
已完结
Tumor Infiltrating Lymphocytes in Breast Cancer
3个月前
已关闭
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
5个月前
已完结
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
6个月前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
7个月前
已完结
Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature
7个月前
已完结
皖公网安备34019202002308
